RUNX2 and acute myeloid leukemia: The combination of SNDX-50469 and the KDM1A inhibitor INCB059872 also exerted synergistic lethality against MOLM13, MV4–11, OCI-AML3, as well as against PD AML cells with MLL1-r or mtNPM1 (Fig. S13A–G).